Cargando…
Targeting colony stimulating factor-1 receptor signalling to treat ectopic pregnancy
1–2% of pregnancies are ectopic, the majority implanting in the Fallopian tube. A single, systemic dose of methotrexate, a DNA-synthesis (S phase) inhibitor, has been used since 1991 for outpatient treatment of women with stable EP. However, methotrexate has limited clinical and cost effectiveness,...
Autores principales: | Ahmad, S. Furquan, Duncan, W. Colin, Campbell, Lisa L., Beaty, Robyn E., Koscielniak, Magda, Collins, Frances, Saunders, Philippa T. K., Horne, Andrew W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519033/ https://www.ncbi.nlm.nih.gov/pubmed/32973322 http://dx.doi.org/10.1038/s41598-020-72785-y |
Ejemplares similares
-
Subsequent pregnancy outcomes among women with tubal ectopic pregnancy treated with methotrexate
por: Mackenzie, Scott C, et al.
Publicado: (2023) -
Pelvic Chlamydial Infection Predisposes to Ectopic Pregnancy by Upregulating Integrin β1 to Promote Embryo-tubal Attachment
por: Ahmad, Syed F., et al.
Publicado: (2018) -
Recent advances in the understanding of tubal ectopic pregnancy
por: Flanagan, Heather C, et al.
Publicado: (2023) -
Ectopic pregnancy and epithelial to mesenchymal transition: is there a link?
por: Flanagan, Heather, et al.
Publicado: (2020) -
The impact of COVID-19 on the assessment and management of ectopic pregnancies
por: Chung, Bethany, et al.
Publicado: (2023)